Subcutaneous anti-CD20 antibody for primary membranous nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and agree by signing consent
- You’re age 18 to 75
- Your “primary” membranous nephropathy was confirmed by a kidney biopsy
- Your blood pressure is reasonably controlled: top number ≤ 140 and bottom number ≤ 90
- If you take blood-pressure medicines like ACE inhibitors or ARBs, your dose must have been stable for at least 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called B007 for people with primary membranous nephropathy, a kidney condition. It aims to see if B007 can help reduce protein in the urine and protect kidney function.
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
This study tests a new drug called JMT601 for people with primary membranous nephropathy, a kidney condition that causes protein in the urine. The goal is to see if JMT601 is safe and effective in reducing protein loss and protecting kidney function.
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.